Eli Lilly Wins FDA Approval for Expanded Jaypirca Use in First-Line Leukemia

Key Facts

The U.S. FDA approved Eli Lilly's drug Jaypirca as a first-line treatment for patients with previously untreated chronic lymphocytic leukemia (CLL). PR Newswire reported that the expanded indication allows the drug to be used for adult patients who have not received prior therapies, moving beyond its previous focus on relapsed or refractory cases.

LLY was trading at $1,138.69 on October 2, 2026, reaching a session high of $1,164.055. This regulatory milestone strengthens the company's oncology portfolio, as the approval is expected to increase the drug's addressable market by targeting patients at the earliest stages of treatment.